Britain’s artificial intelligence sector has produced its first heavyweight league table for 2026, with Barclays placing Oxford-founded chip designer Fractile and Google DeepMind spinout Isomorphic Labs at the center of its new AI 100 ranking, a list that highlights how quickly the UK’s AI economy is maturing.
The bank’s Eagle Labs, a network of high street lenders’ start-up incubators, launched its first ranking this week to identify the country’s fastest-growing AI businesses. Its publication coincides with what is shaping up to be a record year for the sector, with UK AI companies making £8.3bn of investment in 2025 alone and cementing London’s position as Europe’s most thriving AI capital.
For British policymakers, under pressure to deliver on the Prime Minister’s promise to “put AI into the veins” of the economy, the league table comes at a politically charged time. For investors, it provides a useful shortlist of the world’s biggest companies that are in hot pursuit right now.
Oxford chip pioneer joins unicorn club
Few names in the equation have captured the attention of the boardroom like Fractile. The Oxford-based venture, founded in 2022 by former university researcher Walter Goodwin, this week bankrolled a $220m (£165m) Series B round led by Peter Thiel’s Founders Fund, Accel and Factorial Funds joining the cheque.
The round vaults put Fractile in the so-called unicorn bracket and reinforce the belief among the most influential investors in Silicon Valley that the next AI bottleneck will not be smart algorithms, but the eye-watering costs of running them. The firm of Mr. Goodwin is racing to build inference chips that promise to reduce the price of deploying AI models on a commercial scale, an issue that has dominated boardroom discussions from Wall Street to Whitehall.
Industry watchers say the deal is one of the clearest signs yet that British deep-tech, long accused of losing its champions to American consumers, can hold its own in global markets. It also comes at a time when Westminster is relying heavily on the semiconductor sector to support its growth narrative, as it expanded support for chip startups through the ChipStart program.
Isomorphic eyes are a pharma revolution
If Fractile represents the end of the picks and shovels of AI gold, Isomorphic Labs is sitting on the other extreme. The London-based drug discovery business, spun off from Google DeepMind in 2021 under the leadership of Sir Demis Hassabis, recently closed a $2.1bn (£1.57bn) funding round, one of the largest AI raises in Europe to date.
The company is using machine learning to speed up the development of new drugs, an area where pharmaceutical giants have spent years grappling with stubbornly long timelines and ballooning research budgets. Big Pharma is already paying attention: AstraZeneca and Eli Lilly have an inky partnership, and a domestic drug candidate is expected to enter clinical trials before the end of the year.
In an industry where the average new drug takes more than a decade and more than $2bn to bring to market, the prospect of AI compressing that timeline is no longer a fantasy. It’s exactly the kind of productivity sharing that HSBC researchers say could deliver £105bn of cash flow to Britain’s medium-sized companies by 2030 if AI adoption continues.
The boom under observation
But for all the cheesy numbers, Britain’s growing AI investment is not without doubt. A recent investigation by the Guardian asked whether several headline-grabbing promises made by ministers – including data center commitments linked to Nvidia-backed groups Nscale and CoreWeave, had been breached.
This newspaper reported that some of the so-called new infrastructure projects are actually extensions of existing buildings. The Department of Science, Innovation and Technology (DSIT) rejected a number of requests but admitted it “plays no active role in researching these commitments”.
The episode is symptomatic of a broader test of credibility now facing governments around the world as they tout AI as the engine of future growth. The UK has so far announced a £500m Sovereign AI Unit and billions more in computing and infrastructure, but ministers are increasingly being asked to show that eye-catching figures translate into real jobs, industry and tax receipts.
A growing market
Still, the trajectory seems clear. With more than £8bn raised across the sector last year, five new unicorns created and at least 67 exits worth a combined £4bn, the British AI ecosystem no longer trades on potential alone. Smaller players are also benefiting: Eagle Labs’ extensive incubator network, which has supported thousands of regional startups through initiatives such as its £12m regional programme, is increasingly being used as a pipeline builder for the next batch of AI 100 candidates.
For Barclays itself, the standard is a useful part of building a brand among the founders it hopes to bank on for years to come. In Britain, it is a very important thing, the first idea of companies that can, within ten years, sit next to the big established companies of the country.
As one venture capitalist put it this week: “Five years ago, you would have struggled to name three UK AI businesses to support. Today you can’t put them on one page.” With the strength of Barclays’ recent listings, that problem is unlikely to disappear anytime soon.
